Skip to Content
Find More Like This
Return to Search

PIK3CA Mutation Status and SASH1 Expression Predicts Synergy Between Lapatinib and an AKT Inhibitor in HER2 Positive Breast Cancer

United States Patent Application

20130331405
A1
View the Complete Application at the US Patent & Trademark Office
Lawrence Berkeley National Laboratory - Visit the Technology Transfer and Intellectual Property Management Department Website
Methods for identifying a cancer patient, such as a breast cancer patient, suitable for treatment with a 4-anilinoquinazoline kinase inhibitor, such as lapatinib, and an AKT inhibitor, comprising detecting modulated expression of HER2 (ERBB2) and SASH1 or protein encoded thereof and detecting PIK3CA mutation status. High levels of expression in HER2 and high levels of SASH1 and/or positive PIK3CA mutation status indicate a patient that is suitable for treatment with a 4-anilinoquinazoline kinase inhibitor, such as lapatinib and an AKT inhibitor.
Korkola, James E. (West Linn, OR), Gray, Joe W. (Lake Oswego, OR), Bayani, Nora (Berkeley, CA)
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland CA)
13/ 494,918
June 12, 2012
STATEMENT OF GOVERNMENTAL SUPPORT [0001] The invention described was made with government support under Contract No. DE-AC02-05CH11231 awarded by the U.S. Department of Energy, under Work for Others Agreement No. LB06002417, and under Grant No. CA 126551 SPORE grant and Grant No. P50 CA58207 awarded by the National Institutes of Health. The government has certain rights in this invention.